Back to trials View on registry
completed
Phase 3
NCT00970268
A Long-term, Randomized, Double-blind Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide at Two Dose Levels When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Sponsored by AstraZeneca
Why you can trust this information
Registry sourcesNot yet reconciled
Source last updatedNot reported
Clintriva indexed9/27/2026, 9:27:08 PM
Registry records0
Relationships needing review0
Identity-resolution confidence concerns registry/entity resolution and does not determine clinical eligibility.
Interested in this trial?
Express your interest and we'll connect you with the trial team.
Your selected profile and contact information may be shared with an authorised trial site, sponsor, or Clintriva coordination team for trial contact and pre-screening. Expressing interest does not mean you are eligible or enrolled.
Quick Facts
Start DateAug 1, 2009
CompletionOct 1, 2010
Enrollment0/291
CountryUnited States
Conditions
Chronic Obstructive Pulmonary Disease